In vitro and in vivotherapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model

Table 1 Concentrations of chemotherapeutic compounds used in human ovarian cancer cells

Chemotherapeutic compound	Maximal solvent concentration [%]	Maximal chemotherapeutic compound concentration		IC50 [M]
Chemotherapeutic compound	Maximal solvent concentration [%]	Maximal chemotherapeutic compound concentration	SCCOHT-1	SK-OV-3	NIH:OVCAR-3
Cytarabine	1.6 × 10⁰ H₂O	160 μM	8.1 × 10^-6	1.0 × 10^-6	1.1 × 10^-7
Cisplatin	2.0 × 10^–2 NaCl	160 μM	2.3 × 10^-5	3.3 × 10^-6	1.7 × 10^-6
Carboplatin	5.0 × 10^–3 NaCl	160 μM	7.9 × 10^-5	8.8 × 10^-6	7.0 × 10^-6
Cyclophosphamide	7.5 × 10^–3 NaCl	640 μM	1.0 × 10^-5	2.3 × 10^-4	1.0 × 10^-4
Methotrexate	3.0 × 10^–5 NaCl/ 2.0 × 10^–1 PBS	160 nM	4.7 × 10^-9	5.7 × 10^-9	5.9 × 10^-9
Topotecan	7.0 × 10^–3 H₂O/ 2.0 × 10^–1 PBS	160 nM	3.6 × 10^-9	1.8 × 10^-8	5.0 × 10^-9
Doxorubicin	3.0 × 10^–2 H₂O/ 2.0 × 10^–1 PBS	640 nM	2.0 × 10^-8	1.3 × 10^-7	2.9 × 10^-8
5‘-fluorouracil	4.0 × 10^–4 NaCl/ 2.0 × 10^–1 PBS	160 μM	1.9 × 10^-5	3.5 × 10^-6	1.1 × 10^-6
Epothilone A	8.0 × 10^–3 DMSO/ 2.0 × 10^–1 PBS	80 nM	3.3 × 10^-9	2.9 × 10^-9	2.2 × 10^-9
Epothilone B	2.0 × 10^–3 DMSO/ 2.0 × 10^–1 PBS	20 nM	1.5 × 10^-9	2.9 × 10^-10	9.8 × 10^-11
Taxol	6.0 × 10^–4 ethanlol/ 2.0 × 10^–1 PBS	80 nM	2.2 × 10^-9	2.4 × 10^-9	1.4 × 10^-9
Ixabepilone	2.0 × 10^–1 ethanol	40 μM	1.1 × 10^-6	1.6 × 10^-6	9.8 × 10^-7

The maximal chemotherapeutic compound concentration indicates the highest initial concentration on the cells in the well followed by 2-fold serial dilutions.
The IC50 values of the appropriate chemotherapeutic compounds were calculated from the drug-dose–response curves after normalization to the mean signal of the cells-only control and then to the mean signal of the solvent-only control.

ISSN: 1750-1172